Exercise of warrants Proceeds from Warrant Exercises Asset Held for Sale Asset Held For Sale [Policy Text Block] Asset Held For Sale Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Leasehold improvements Leasehold Improvements [Member] Net loss Net loss Net loss Net loss - basic and diluted Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Right-of-use assets, net Operating Lease, Right-of-Use Asset Exit and Disposal Activities Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Convertible preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Employee-related Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Entity Address, Address Line One Entity Address, Address Line One Forfeited (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Entity Filer Category Entity Filer Category Restructuring Type [Axis] Restructuring Type [Axis] Weighted-average remaining lease terms—operating leases (years) Operating Lease, Weighted Average Remaining Lease Term Other assets Other Assets, Noncurrent Options not yet exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Not Yet Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Not Yet Exercisable, Number Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Net increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Aggregate intrinsic value, exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Warrants Exchanged For Common Stock Warrants Exchanged For Common Stock [Member] Warrants Exchanged For Common Stock Document Fiscal Year Focus Document Fiscal Year Focus Subsequent Event Type [Domain] Subsequent Event Type [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Preferred stock, outstanding Preferred Stock, Value, Outstanding Variable lease cost Variable Lease, Cost Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Weighted-average discount rate—operating leases Operating Lease, Weighted Average Discount Rate, Percent Number of vaccination dose regimen Number of Vaccination Dose Regimen Number of Vaccination Dose Regimen Aggregate Intrinsic Value (in thousands) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Research and development Research and Development Expense [Member] Sale of Stock [Axis] Sale of Stock [Axis] Subsequent Events [Abstract] Subsequent Events [Abstract] Impairment on note receivable Financing Receivable, Credit Loss, Expense (Reversal) Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Granted (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Total property and equipment Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Operating lease, number of renewal terms Lessee, Operating Lease, Number of Renewal Terms Lessee, Operating Lease, Number of Renewal Terms Beginning balance Ending balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Award Type [Domain] Award Type [Domain] Options to purchase common stock Equity Option [Member] Aggregate intrinsic value, forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Forfeitures In Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Forfeitures In Period Assets Assets [Abstract] Additional Disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Collaboration revenue Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Options exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Pronouncements or Change in Accounting Principle [Line Items] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Preferred stock issued Preferred Stock, Value, Issued Property and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Options outstanding, beginning balance (in shares) Number of shares, options outstanding, beginning balance (in shares) Number of shares, options outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Entity Address, City or Town Entity Address, City or Town Accumulated Deficit Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Non-current liabilities Liabilities, Noncurrent [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Fair value of consideration transferred to settle warrants in excess of fair value of warrants Class Of Warrant Or Right, Consideration Transferred In Excess Of Fair Value Class Of Warrant Or Right, Consideration Transferred In Excess Of Fair Value Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Clinical Accrued Liabilities, Clinical Accrued Liabilities, Clinical Expected milestone payment Class of Warrant or Right, Expected Milestone Payment Class of Warrant or Right, Expected Milestone Payment Purchase of property and equipment Capital Expenditures Incurred but Not yet Paid Series A Warrants Series A Warrants [Member] This member stands for Series A Warrants. Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Supplemental Balance Sheet Information Related to Leases Supplemental Balance Sheet Information, Leases Disclosure [Table Text Block] Supplemental Balance Sheet Information, Leases Disclosure Financing lease principal payments Finance Lease, Principal Payments Entity Interactive Data Current Entity Interactive Data Current Number of operating segments Number of Operating Segments Net loss per share of common stock - basic (in USD per share) Net loss per common share - basic and diluted (in USD per share) Earnings Per Share, Basic 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Vaccination dose regimen, duration apart Vaccination Dose Regimen, Duration Apart Vaccination Dose Regimen, Duration Apart Beginning balance outstanding (in shares) Ending balance outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Document Type Document Type Agreement to sell, price per share (in USD per share) Sale of Stock, Agreement to Sell, Price Per Share Sale of Stock, Agreement to Sell, Price Per Share Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Entity Current Reporting Status Entity Current Reporting Status Number of series of warrants issued Number Of Series of Warrants Issued Number Of Series of Warrants Issued Machinery and equipment Machinery and Equipment [Member] Number of shares authorized for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Other non-cash Other Noncash Income (Expense) Number of employees given notice of termination Restructuring and Related Cost, Number of Positions Eliminated Principal outstanding Long-term Debt, Gross Options, vested in period, fair value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Plan Name [Axis] Plan Name [Axis] Total carrying value of debt, net Carrying value Long-term Debt Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Non-cash interest expense Non-Cash Interest Expense Amount of non-cash interest expense during the period. Document Transition Report Document Transition Report Consideration transferred, warrant exchange promissory notes Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Promissory Note Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Promissory Note Single gene replacement therapies, number of genetic mutations target Single Gene Replacement Therapies, Number Of Genetic Mutations Target Single Gene Replacement Therapies, Number Of Genetic Mutations Target Estimated base rent payments Base Rent Payments, Expected Cost Base Rent Payments, Expected Cost Total liabilities and stockholders’ equity Liabilities and Equity Other Other Accrued Liabilities, Current Weighted average exercise price, exercised (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Additional paid-in capital Additional Paid in Capital Number of equity compensation plans Number Of Equity Compensation Plans Number Of Equity Compensation Plans Supplemental disclosure of non-cash investing and financing transactions: Supplemental Cash Flow Elements [Abstract] Equity issuance costs Noncash Or Part Noncash Amount of Deferred Transaction Cost Amount of noncash or part noncash amount of deferred transaction cost. Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Net Loss Per Share of Common Stock Earnings Per Share [Text Block] Operating expenses Operating Expenses [Abstract] Issuance of common stock for option exercises Stock Issued During Period, Value, Stock Options Exercised Leases, term of contract for additional lease agreement Lessee, Operating Lease, Term Of Contract For Additional Lease Agreement Lessee, Operating Lease, Term Of Contract For Additional Lease Agreement Minimum Minimum [Member] Forgiveness of PPP Note Gain (Loss) On Forgiveness Of Paycheck Protection Program Note Gain (Loss) On Forgiveness Of Paycheck Protection Program Note Company borrowed Long-term Line of Credit 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Class of Warrant or Right Class of Warrant or Right [Line Items] Weighted average exercise price, cancelled (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Less: unamortized debt issuance costs Debt Issuance Costs, Net Convertible preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Trading Symbol Trading Symbol At-the-market Issuance ATM Transactions [Member] ATM Transactions Current liabilities Liabilities, Current [Abstract] Number of additional lease agreement extensions Number Of Additional Lease Agreement Extensions Number Of Additional Lease Agreement Extensions Class of Warrant or Right [Table] Class of Warrant or Right [Table] Issuance of stock Stock Issued During Period, Value, New Issues Professional fees Accrued Liabilities, Professional Fees Accrued Liabilities, Professional Fees General and administrative General and Administrative Expense Debt Debt Disclosure [Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Weighted average exercise price, options exercisable (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock-based Compensation Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Less: accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Notes Receivable Loans, Notes, Trade and Other Receivables, Excluding Allowance for Credit Losses [Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Beginning balance, weighted average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Efficacy against delta variant, B.1.617.2 (percentage) Efficacy Against Delta Variant, B.1.617.2, Percent Efficacy Against Delta Variant, B.1.617.2, Percent Payment of equity issuance costs Payments of Stock Issuance Costs Issuance of stock (in shares) Stock Issued During Period, Shares, New Issues Total lease liabilities Present value of minimum lease payments Operating Lease, Liability Issuance of common stock for option and warrant exercises (in shares) Stock Issued During Period, Shares, Options And Warrants Exercised Stock Issued During Period, Shares, Options And Warrants Exercised Common stock; $0.01 par value; 295,000,000 and 200,000,000 shares authorized, 199,049,329 and 184,133,384 shares issued, and 198,927,829 and 184,011,884 shares outstanding at September 30, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Deemed dividend related to Warrant Exchange Preferred Stock Dividends and Other Adjustments Total other income (expense) Nonoperating Income (Expense) Unrecognized compensation expense related to options outstanding, weighted average period for expense to be recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Beginning balance (in USD per share) Ending balance (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Basis of Presentation and Consolidation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies (Note 13) Commitments and Contingencies Subsequent Event [Table] Subsequent Event [Table] Operating Leases Lessee, Operating Leases [Text Block] Remainder of 2021 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Additional payment Collaboration Agreement, Additional Payment Within 30 Days Of First Commercial Sale In Canada Collaboration Agreement, Additional Payment Within 30 Days Of First Commercial Sale In Canada Payments of debt issuance costs Payments of Debt Issuance Costs Receivables [Abstract] Proceeds from issuance of debt Proceeds from Issuance of Debt Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Right-of-use asset related to operating leases Noncash or Part Noncash, Operating Lease, Right-of-Use Asset Right-to-use asset recognized upon adoption of ASU 2018-11. Document Period End Date Document Period End Date Severance-related Accrued Severance-Related Liabilities, Current Accrued Severance-Related Liabilities, Current Class of Stock [Axis] Class of Stock [Axis] Entity Registrant Name Entity Registrant Name Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Number of warrants outstanding (in shares) Class of Warrant or Right, Outstanding Less: present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Aggregate intrinsic value, granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted Accredited investors agreement to cancel outstanding obligation Sale Of Stock, Outstanding Obligation Cancelled In Exchange For Stock Sale Of Stock, Outstanding Obligation Cancelled In Exchange For Stock 2014 Plan 2014 Plan [Member] 2014 Plan Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Financial Instrument [Axis] Financial Instrument [Axis] Promissory note, interest rate Financing Receivable, Interest Rate, Stated Percentage Financing Receivable, Interest Rate, Stated Percentage Commissions, fees and expenses Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Equity [Abstract] Equity [Abstract] Measurement Input Type [Domain] Measurement Input Type [Domain] Common Stock Common Stock [Member] Interest income Investment Income, Interest Loss from operations Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating lease obligation Current lease obligations Operating Lease, Liability, Current License and Development Agreements Collaborative Arrangement Disclosure [Text Block] Treasury stock (in shares) Treasury Stock, Common, Shares Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Property, Plant and Equipment [Abstract] Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation expense Depreciation Repayments of debt Repayments of debt Repayments of Debt Non-cash lease expense Noncash Lease Expense Noncash Lease Expense Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Warrant Exchange Promissory Notes Warrant Exchange Promissory Notes [Member] Warrant Exchange Promissory Notes Treasury Stock Treasury Stock [Member] Plus: accrued interest Interest Payable Agreement to sell, number of shares issued in transaction (in shares) Sale of Stock, Agreement to Sell, Number of Shares Issued in Transaction Sale of Stock, Agreement to Sell, Number of Shares Issued in Transaction Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Share-based Payment Arrangement, Restricted Stock Unit, Activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Other income (expense) Other Nonoperating Income (Expense) Obligation settled with common stock Stock Issued Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Award Type [Axis] Award Type [Axis] Weighted average exercise price, granted (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Aggregate intrinsic value, beginning balance Aggregate intrinsic value, ending balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Maturities of Operating Leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Measurement Input Type [Axis] Measurement Input Type [Axis] Issuance of Warrant Exchange Promissory Notes Notes Issued Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Warrants Warrants [Text Block] Warrants Common stock, shares issued (in shares) Common Stock, Shares, Issued Convertible preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Aggregate intrinsic value, options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value SPA Warrants SPA Warrants [Member] SPA Warrants Gain on forgiveness of PPP Note Gain on extinguishment of debt Gain (Loss) on Extinguishment of Debt Research and development Research And Development Expenses Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Overall vaccine efficacy (percentage) Overall vaccine efficacy, Percent Overall vaccine efficacy, Percent Useful life (in years) Property, Plant and Equipment, Useful Life Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Issuance of note receivable Issuance Of Financing Receivable Issuance Of Financing Receivable Aggregate intrinsic value, forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Operating lease obligation, less current portion Non-current lease obligations Operating Lease, Liability, Noncurrent Aggregate amount Debt Instrument, Face Amount Interest expense Interest Expense Canada Consulting Warrants Canada Consulting Warrants [Member] Canada Consulting Warrants City Area Code City Area Code Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Leases, term of contract (in years) Lessee, Operating Lease, Term of Contract Expiration period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period RSUs Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Amendment Flag Amendment Flag Income tax benefit Income Tax Expense (Benefit) Supply agreement, number of doses Supply Agreement, Number of Doses Supply Agreement, Number of Doses Modifier gene therapy platform, number of products Modifier Gene Therapy Platform, Number of Products Modifier Gene Therapy Platform, Number of Products Equity Components [Axis] Equity Components [Axis] Machinery Machinery [Member] Machinery Antidilutive Securities [Axis] Antidilutive Securities [Axis] Total current assets Assets, Current Total Lessee, Operating Lease, Liability, to be Paid Sale of Stock [Domain] Sale of Stock [Domain] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Entity File Number Entity File Number Stock-based compensation Share-based Payment Arrangement [Policy Text Block] Warrant Exchange (in shares) Stock Issued During Period, Shares, Warrant Exchange Stock Issued During Period, Shares, Warrant Exchange Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Small Business Entity Small Business COVAXIN Preferred Stock Purchase Agreement COVAXIN Preferred Stock Purchase Agreement [Member] COVAXIN Preferred Stock Purchase Agreement Convertible preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Options, grants in period, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Fair value of consideration transferred to settle warrants Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Notes payable Notes Payable to Banks [Member] Statement [Line Items] Statement [Line Items] OpCo Warrants OpCo Warrants [Member] OpCo Warrants Property and equipment, net Total property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Efficacy, severe cases (percentage) Efficacy, Severe Cases, Percent Efficacy, Severe Cases, Percent Restricted cash Restricted Cash, Noncurrent Upfront payment Collaboration Agreement, Upfront Payment Collaboration Agreement, Upfront Payment Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Registered Direct Offering Registered Direct Offering [Member] Registered Direct Offering Series B Preferred Stock Series B Warrants Series B Preferred Stock [Member] Schedule of Cash, Cash Equivalents, and Restricted Cash Schedule of Cash and Cash Equivalents, Restricted Cash [Table Text Block] Tabular disclosure of the components of cash and cash equivalents, restricted cash. 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Debt Disclosure [Abstract] Debt Disclosure [Abstract] Accrued Liabilities, Current [Abstract] Accrued Liabilities, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Type of Restructuring [Domain] Type of Restructuring [Domain] Number of former employees with warrants Number Of Former Employees With Warrants Number Of Former Employees With Warrants Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Schedule of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Entity Shell Company Entity Shell Company Local Phone Number Local Phone Number Schedule of Stock-based Compensation Expense for Options Granted Reflected in the Consolidate Statement of Operations and Comprehensive Loss Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Preferred stock, measurement input Preferred Stock, Measurement Input Preferred Stock, Measurement Input Advance for COVAXIN supply Advances on Inventory Purchases Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Total assets Assets Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Number of ODDs received (orphan drug designation) Number Of Orphan Drug Designations Number Of Orphan Drug Designations Net loss to common stockholders Net Income (Loss) Available to Common Stockholders, Diluted Expected severance benefits to be paid Restructuring and Related Cost, Expected Cost Adverse events, side effects (percentage) Adverse Events, Side Effects, Percent Adverse Events, Side Effects, Percent Net loss to common stockholders Net Income (Loss) Available to Common Stockholders, Basic PPP Note PPP Note Paycheck Protection Program Loan [Member] Paycheck Protection Program Loan Interest rate Debt Instrument, Interest Rate, Stated Percentage ATMs Controlled Equity Offering Sales Agreement [Member] Controlled Equity Offering Sales Agreement Warrant Exchange Stock Issued During Period, Value, Warrant Exchange Stock Issued During Period, Value, Warrant Exchange Lease renewal term (in years) Lessee, Operating Lease, Renewal Term Number of at-the-market offerings Number Of At-The-Market Offerings Number Of At-The-Market Offerings Total non-current liabilities Liabilities, Noncurrent Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Short-term debt, net Short-term Debt Furniture and fixtures Furniture and Fixtures [Member] In-process research and development Research and Development in Process Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Components of Lease Expense Lease, Cost [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Subsequent Events Subsequent Event [Line Items] Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Net loss per share of common stock - diluted (in USD per share) Earnings Per Share, Diluted Shares used in calculating net loss per common share - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Price per share (in USD per share) Sale of Stock, Price Per Share Subsequent Events Subsequent Events [Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Net loss and comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Severance-related charges Employee Severance [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Treasury stock, at cost, 121,500 shares at September 30, 2021 and December 31, 2020 Treasury Stock, Value Loans payable Loans Payable [Member] Award vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Restructuring charges Restructuring Charges Accounts payable Accounts Payable, Current Series B Warrants Series B Warrants [Member] This member stands for Series B Warrants. Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Accredited investors agreement to cancel additional portion owed representing a discount Sale Of Stock, Additional Debt Cancelled In Exchange For Stock Sale Of Stock, Additional Debt Cancelled In Exchange For Stock Financial Instruments [Domain] Financial Instruments [Domain] Borrowing increments Line Of Credit Borrowing Each Draw The amount of borrowing that can be borrowed each draw from a line of credit Revenues Revenues [Abstract] Issuance of common stock for option and warrant exercises Stock Issued During Period, Value, Options And Warrants Exercised Stock Issued During Period, Value, Options And Warrants Exercised Income tax benefit Income Tax Credits and Adjustments Consideration transferred, common stock Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Common Stock Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Common Stock Asset acquisition Payments to Acquire Intangible Assets Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Total lease cost Lease, Cost Major Components of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Total operating expenses Operating Expenses Class of warrant or right, exercisable (in shares) Class of Warrant or Right, Exercisable Class of Warrant or Right, Exercisable 2019 Plan 2019 Plan [Member] 2019 Plan Collaboration Arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Schedule of Debt Schedule of Long-term Debt Instruments [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Covaxin Agreement Collaborative Arrangement [Member] Property, plant and equipment, gross Property, Plant and Equipment, Gross Accrued Expenses and Other Current Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Document Quarterly Report Document Quarterly Report Other assets Increase (Decrease) in Other Operating Assets Total revenues Revenues Series B Convertible Preferred Stock issuance Proceeds from Issuance of Preferred Stock and Preference Stock Initial exercise price (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Severance costs Severance Costs Beginning balance, weighted average exercise price (in USD per share) Ending balance, weighted average exercise price (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Warrants Warrant [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Collaboration Agreement Term Collaboration Agreement Term Collaboration Agreement Term Long term debt, net Long-term Debt, Excluding Current Maturities Stock-based compensation expense Share-based Payment Arrangement, Expense Weighted average remaining contractual life, options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Subscription Agreements and Warrant Exercises Subscription Agreements And Warrant Exercises [Member] Subscription Agreements And Warrant Exercises Weighted- Average Grant-Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Convertible preferred stock, shares issued upon conversion (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Series A Preferred Stock Series A Preferred Stock [Member] Series C Warrants Series C Warrants [Member] This member stands for Series C Warrants. Lease obligations Increase (Decrease) In Lease Obligations Increase (Decrease) In Lease Obligations EB-5 Loan Agreement E B5 Program Borrowings [Member] Represents borrowings from the U.S. government's Immigrant Investor Program, commonly known as the EB 5 program (the "EB 5 Program"). Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Construction in progress Construction in Progress [Member] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, cash equivalents and restricted cash Total cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Number of shares issued and sold Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Discount Rate Measurement Input, Discount Rate [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Current assets Assets, Current [Abstract] Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name Issuance of common stock for option exercises (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Shares used in calculating net loss per common share - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Fair value of warrants Warrants and Rights Outstanding Profits generated, shared percentage Collaborative Arrangement, Profits Generated, Shared, Percentage Collaborative Arrangement, Profits Generated, Shared, Percentage Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Schedule of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of Potentially Dilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other income (expense) Nonoperating Income (Expense) [Abstract] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] General and administrative General and Administrative Expense [Member] Principles of Consolidation Consolidation, Policy [Policy Text Block] Total current liabilities Liabilities, Current Class of Stock [Domain] Class of Stock [Domain] Maximum borrowing Line of Credit Facility, Maximum Borrowing Capacity Entity Address, Postal Zip Code Entity Address, Postal Zip Code Promissory note Financing Receivable, before Allowance for Credit Loss Subscription Agreements Subscription Agreements [Member] Subscription Agreements Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Title of 12(b) Security Title of 12(b) Security Statement [Table] Statement [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Recently Adopted Accounting Standards and Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Asset held for sale Assets Held-for-sale, Not Part of Disposal Group, Current Unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Adverse events, serious adverse side effects (less than) (percentage) Adverse Events, Serious Adverse Side Effects, Percent Adverse Events, Serious Adverse Side Effects, Percent Efficacy, asymptomatic infection (percentage) Efficacy, Asymptomatic Infection, Percent Efficacy, Asymptomatic Infection, Percent Statistical Measurement [Axis] Statistical Measurement [Axis] Subsequent Event Subsequent Event [Member] Cover [Abstract] Preferred Stock Preferred Stock [Member] Share-based Payment Arrangement, Performance Based Option Share-based Payment Arrangement, Performance Based Option [Member] Share-based Payment Arrangement, Performance Based Option Collaboration Agreement With Cansino Biologics Collaboration Agreement With Cansino Biologics [Member] Collaboration Agreement With Cansino Biologics Nature of Business Nature of Operations [Text Block] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Financing lease right-of-use asset Finance Lease, Right-of-Use Asset, before Accumulated Amortization Operating lease cost Operating Lease, Cost Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]